This combined synopsis/solicitation under FAR Part 12 is the only solicitation and seeks quotations for commercial services to facilitate research, programmatic, and operational support of the National ALS Biorepository in support of the ALS Registry Act. The acquisition is set aside for small business concerns. The anticipated period of performance is 9/28/2026 through 9/27/2031, inclusive of the base period and all option periods. Provisions, clauses, line items, quantities, requirements, and delivery/acceptance details are incorporated by reference and available in the solicitation document. Offers are requested, and no separate written solicitation will be issued.

This is a combined synopsis/solicitation for commercial products or services under FAR Part 12, issued as a Request for Quotation with no separate written solicitation. The project is to facilitate research, programmatic, and operational support of the National Amyotrophic Lateral Sclerosis (ALS) Biorepository in support of the ALS Registry Act. The acquisition is set aside for small business concerns. The anticipated period of performance is 9/28/2026 through 9/27/2031, inclusive of the base period and all option periods. Attachment 1, the Artificial Intelligence (AI) Use Compliance and Risk Management Plan, has been added.